Literature DB >> 1301938

A mutation common in non-Jewish Tay-Sachs disease: frequency and RNA studies.

B R Akerman1, J Zielenski, B L Triggs-Raine, E M Prence, M R Natowicz, J S Lim-Steele, M M Kaback, E H Mules, G H Thomas, J T Clarke.   

Abstract

Tay-Sachs disease (TSD) is an autosomal recessive genetic disorder resulting from mutation of the HEXA gene encoding the alpha-subunit of the lysosomal enzyme, beta-N-acetylhexosaminidase A (Hex A). We have discovered that a Tay-Sachs mutation, IVS-9 + 1 G-->A, first detected by Akli et al. (Genomics 11:124-134, 1991), is a common disease allele in non-Jewish Caucasians (10/58 alleles examined). A PCR-based diagnostic test, which detects an NlaIII site generated by the mutation, revealed a frequency among enzyme-defined carriers of 9/64 (14%). Most of those carrying the allele trace their origins to the United Kingdom, Ireland, or Western Europe. It was not identified among 12 Black American TSD alleles or in any of 18 Ashkenazi Jewish, enzyme-defined carriers who did not carry any of the mutations common to this population. No normally spliced RNA was detected in PCR products generated from reverse transcription of RNA carrying the IVS-9 mutation. Instead, the low levels of mRNA from this allele were comprised of aberrant species resulting from the use of either of two cryptic donor sites, one truncating exon 9 and the other within IVS-9, spliced to exon 10. Numerous additional splice products were detected, most involving skipping of one or more surrounding exons. Together with a recently identified allele responsible for Hex A pseudodeficiency (Triggs-Raine et al. Am J Hum Genet, 1992), these two alleles accounted for almost 50% (29/64) of TSD or carrier alleles ascertained by enzyme screening tests in non-Jewish Caucasians.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301938     DOI: 10.1002/humu.1380010407

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  10 in total

Review 1.  Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on β-hexosaminidase activity in Sandhoff fibroblasts.

Authors:  Elena Chiricozzi; Natalia Niemir; Massimo Aureli; Alessandro Magini; Nicoletta Loberto; Alessandro Prinetti; Rosaria Bassi; Alice Polchi; Carla Emiliani; Catherine Caillaud; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-12-20       Impact factor: 5.590

2.  Molecular characterization of both alleles in an unusual Tay-Sachs disease B1 variant.

Authors:  M B Coulter-Mackie
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

3.  Novel mutations and DNA-based screening in non-Jewish carriers of Tay-Sachs disease.

Authors:  B R Akerman; M R Natowicz; M M Kaback; M Loyer; E Campeau; R A Gravel
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.

Authors:  Brian L Mark; Don J Mahuran; Maia M Cherney; Dalian Zhao; Spencer Knapp; Michael N G James
Journal:  J Mol Biol       Date:  2003-04-11       Impact factor: 5.469

5.  Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.

Authors:  Gustavo H B Maegawa; Michael Tropak; Justin Buttner; Tracy Stockley; Fernando Kok; Joe T R Clarke; Don J Mahuran
Journal:  J Biol Chem       Date:  2007-01-21       Impact factor: 5.157

6.  Heterozygosity for Tay-Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain.

Authors:  M van Bael; M R Natowicz; J Tomczak; E E Grebner; E M Prence
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

7.  Further investigation of the HEXA gene intron 9 donor splice site mutation frequently found in non-Jewish Tay-Sachs disease patients from the British Isles.

Authors:  E C Landels; P M Green; I H Ellis; A H Fensom; M M Kaback; J Lim-Steele; K Zeiger; N Levy; M Bobrow
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

8.  Mutational analyses of Tay-Sachs disease: studies on Tay-Sachs carriers of French Canadian background living in New England.

Authors:  B Triggs-Raine; M Richard; N Wasel; E M Prence; M R Natowicz
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

9.  A second mutation associated with apparent beta-hexosaminidase A pseudodeficiency: identification and frequency estimation.

Authors:  Z Cao; M R Natowicz; M M Kaback; J S Lim-Steele; E M Prence; D Brown; T Chabot; B L Triggs-Raine
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

10.  Late-Onset Tay-Sachs Disease in an Irish Family.

Authors:  Stela Lefter; Olivia O' Mahony; Brian Sweeney; Aisling M Ryan
Journal:  Mov Disord Clin Pract       Date:  2020-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.